Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Erasca's Sloan Ratio for the quarter that ended in Mar. 2024 was 20.87%.
As of Mar. 2024, Erasca has a Sloan Ratio of 20.87%, indicating there is a warning stage of accrual build up.
Erasca Sloan Ratio % Historical Data
The historical data trend for Erasca's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Erasca's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Erasca's Sloan Ratio % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Erasca's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Erasca's Sloan Ratio % falls into.
Erasca Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Erasca's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Erasca's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was -31.781 (Jun. 2023 ) + -30.361 (Sep. 2023 ) + -29.701 (Dec. 2023 ) + -35.017 (Mar. 2024 ) = $-126.86 Mil.
Erasca's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was -25.951 (Jun. 2023 ) + -24.12 (Sep. 2023 ) + -24.788 (Dec. 2023 ) + -33.251 (Mar. 2024 ) = $-108.11 Mil.
Erasca's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was -108.667 (Jun. 2023 ) + -1.812 (Sep. 2023 ) + 4.545 (Dec. 2023 ) + 9.971 (Mar. 2024 ) = $-95.96 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Erasca (NAS:ERAS) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2024, Erasca has a Sloan Ratio of 20.87%, indicating there is a warning stage of accrual build up.
Erasca Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Erasca's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ERAS has been successfully added to your 